Shares of BillionToOne (NASDAQ:BLLN) tumbled nearly 39% on Thursday, marking one of the steepest single-day declines for the molecular diagnostics company since its public listing. The sell-off came despite a robust second-quarter earnings report, as investors zeroed in on the company's decision to maintain its full-year guidance, which implies a significant deceleration in growth during the second half of 2026.
As of 3:03 p.m. EDT, the stock was trading at $91.72, down 38.8% from the previous close. Trading volume surged to nearly four times the 65-day average, reflecting intense investor activity. The decline erased approximately $2.75 billion in market capitalization based on shares outstanding as of August 3.
Strong Q2 Results, but Guidance Raises Concerns
BillionToOne reported second-quarter revenue of $109.4 million, a 64% year-over-year increase. The company maintained its full-year forecast of $450 million to $465 million, which implies second-half growth of roughly 29% to 38% compared to the 74% growth achieved in the first half. This guidance suggests that average quarterly revenue in the back half would be just 9.5% higher than Q2 levels, a pace that disappointed investors who had bid the stock up more than 84% following its May earnings report.
"The market is not dismissing the quarterly results but is instead adjusting valuations for the second half's exit rate," noted analysts. The company's first-half revenue reached $217.8 million, up 74% from the prior year. To meet the full-year guidance, second-half revenue must range between $232.2 million and $247.2 million.
Operational Highlights and Segment Performance
Despite the stock's reaction, the quarter showcased solid operational metrics. Test volume expanded 35% year-over-year, while average selling price increased 21%. Gross margin stood at 70.5%, and the company posted operating profit of $5.5 million, a turnaround from the $1.6 million operating loss in the same period last year. Adjusted EBITDA came in at $16.1 million.
Oncology continued to be the fastest-growing segment, with revenue surging 176% to $13.7 million. Prenatal clinical services revenue climbed 55% to $94.2 million. However, sequential revenue growth was modest, up just 1% from Q1, though it rose 8% when excluding reimbursement true-ups. The company retained over $10 million in claims amid national-payor code changes, which masked underlying momentum.
Peer Comparison and Analyst Reactions
The market's reaction was starkly contrasted with that of peer Caris Life Sciences (NASDAQ:CAI), which saw its shares jump 16.4% after raising its full-year guidance, despite reporting slower 45% revenue growth. GRAIL (NASDAQ:GRAL) fell 17.2% after posting a wider net loss and facing an upcoming FDA advisory committee review. This divergence underscores investors' intense focus on forward guidance rather than past performance.
Analysts were quick to adjust their views. BTIG's Mark Massaro maintained a Buy rating but lowered his price target to $130 from $142, still representing a 42% premium to the current price. William Blair's Matt Larew described BillionToOne as "a victim of its own success." Overall, the stock has six Buy ratings and two Holds, with a mean price target of $121.43, about 32% above current levels.
Valuation and Risks
Even after the steep decline, the stock remains richly valued. With shares at $91.72, equity is valued at approximately $4.33 billion. After adjusting for $548.6 million in cash and $91 million in debt, the enterprise value stands at about 8.5 times the midpoint of projected 2026 revenue.
Investors are also weighing several risks: over 90% of first-half revenue came from third-party reimbursement, accounts receivable have surged 80% since December to $74.9 million, and accelerating oncology growth could pressure margins as those tests are currently less profitable. Upcoming product launches, including a 130-gene fetal-risk panel on August 17 and Northstar Origin on September 1, will be closely watched as catalysts.
As the market digests this sharp correction, the key question remains whether the maintained guidance reflects conservative management or a genuine slowdown. Investors will be monitoring reimbursement collections, ASP trends, and the success of new product launches for clues.
